Results 231 to 240 of about 6,329,421 (270)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Antenatal depressive symptoms impair offspring neurodevelopment by inducing maternal gut microbiota dysbiosis during pregnancy. [PDF]

open access: yesGut Microbes
Zhou F   +13 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen   +14 more
wiley   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

ÐикоÑиÑÑÐ°Ð½Ð½Ñ ÐºÐ¾ÑÑÐ½Ð½Ñ ÐºÑлÑбаби лÑкаÑÑÑÐºÐ¾Ñ (Taraxacum officinale Wigg.) Ð´Ð»Ñ Ð¾Ð´ÐµÑÐ¶Ð°Ð½Ð½Ñ ÑÑкÑовмÑÑÐ½Ð¸Ñ ÐºÐ¾Ð½ÑенÑÑаÑÑв

open access: green, 2017
Косоголова, Л. О.; Національний авіаційний університет   +3 more
openalex   +1 more source

Home - About - Disclaimer - Privacy